John O. Prior, PhD MD, FEBNM has been Professor and Head of Nuclear Medicine and Molecular Imaging at Lausanne University Hospital, Switzerland since 2010. After graduating with a MSEE degree from the Swiss Federal Institute of Technology at Zurich (ETH Zurich), he received a PhD in Biomedical Engineering from The University of Texas Southwestern Medical Center at Dallas (UTSW) and a MD from the University of Lausanne. He underwent thereafter specialization training in nuclear medicine in Lausanne and a visiting associate professor fellowship at the University of California at Los Angeles (UCLA).

Prof. Prior is currently President of the Swiss Society of Nuclear Medicine, Chair of the UEMS/EANM Accreditation Committee of Nuclear Medicine Department and Training Centers, and Member of the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and past member of the SNMMI Board of Director of the PET Center of Excellence, as well as IEEE Senior Member. His research interests are in molecular imaging and therapy using radiopharmaceuticals.

Orazio Schillaci MD PhD has been Professor of Nuclear Medicine at the University of Rome “La Vergata” since 2007 and Dean of the Faculty of Medicine and Surgery at the University of Rome “La Vergata” since 2013. He received his Degree in Medicine and Surgery and his PhD in Functional Radioisotope Imaging from the University of Rome “La Sapienza” and from 2006 to 2009 served as Expert of the Hight Council of the Italian Ministry of Health. From 2001 Prof Schillaci was Chief Nuclear Medicine UOC, Tor Vergata University Hospital, Rome, and in 2018 was appointed Chief Departmento of Oncoematology.

Since March 2017 Prof. Schillaci has been President of the Italian Association of Nuclear Medicine (AIMN). He has also been Chairman to several high profile meetings including EANM and SNMMI.

Prof. Schillaci is Editor of the European Journal of Nuclear Medicine and Molecular Imaging and of The Journal of Nuclear Medicine, the most prestigious journal in the world in the field of Nuclear Medicine. He is also Editor of several other high profile journals. Prof. Schillaci is author of more than 400 scientific publications, and his research areas are oncology, cardiology, radioembolization, neurology imaging of Alzheimer’s and Parkinson’s diseases, imaging fusion with hybrid devices (SPECT/CT and PET/CT) and personalized medicine.

Prof. Sartor, MD received his MD from Tulane University with honors in 1982. He has served as a Senior Investigator at the NCI focusing on novel therapeutics for advanced prostate cancer patients. In July 2010, Prof. Sartor was named Medical Director of the Tulane Cancer Center.

Prof. Sartor’s interests have focused broadly on prostate cancer, predominantly in patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel in prostate cancer.

He is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center and the Laborde Professor for Cancer Research, with appointments in both the Medicine and Urology Departments. He is also a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).

Dr Ian Wilson, PhD is a graduate of the University of Manchester with over 25 years of experience in the commercial development of in vivo medical diagnostics and imaging medical devices. Ian is currently COO of ImaginAb Inc, an imaging company developing next generation molecular imaging agents using Minibody technology. Before join ImaginAb, and for the last 3 years, Ian was CEO and CTO of Edinburgh Molecular Imaging Ltd., leading the development of novel optical imaging agents to improve cancer detection, surgery, and lung disease.

In a previous position at Xstrahl Ltd., as CTO &COO, Ian was responsible for the oversight of Radiotherapy commercial operations and manufacturing, including new product development. Between 1996 and 2013, Ian held numerous roles at GE Healthcare including Portfolio and Strategy Manager and Head of Biology. While at GE Healthcare, Ian was responsible for the management of GE Healthcare’s Molecular Imaging Agent Portfolio, in Cardiovascular, Oncology & Neurology, and strategic & tactical oversight. Ian was also responsible for supporting the efficacy and regulatory studies required for the approval of new imaging agents.

Since 2006 Prof. Philip Blower, DPhil has been at King’s College London as Chair in Imaging Chemistry in the Division of Imaging Sciences and Biomedical Engineering. His research interests are best summarised as “molecular imaging” mainly using inorganic chemistry tools. As Head of the Imaging Chemistry and Biology Dept., he has built a large interdisciplinary research group with wide interests covering radiopharmaceutical chemistry and biology for PET, SPECT and radionuclide therapy, applying inorganic chemistry from all parts of the periodic table to nuclear medicine. He has published ca. 180 peer-reviewed papers and supervised 33 successful PhD students. He led the setting up of the new Chemistry Division and its undergraduate programme at King’s in 2012 and served as its first interim Head. He has served on various peer review panels for international grant awarding bodies and journals and as Editor in Chief of Nuclear Medicine Communications. His path to this point followed a BA in Natural Sciences (Cambridge) and DPhil in Chemistry (Sussex), and postdoctoral experience in inorganic chemistry at Indiana University and Oxford University. His first academic post was a joint appointment at Kent and Canterbury Hospital (Radiopharmacy) and the University of Kent (Biosciences).

One of the prominent current areas of interest currently is leading a multidisciplinary team of academics at King’s developing advanced radionuclide methods for in vivo cell tracking in the whole body by PET and multimodality imaging, using direct labelling and reporter gene approaches.

Since 2012, Dr Thomas Reiner has been a faculty member at the Department of Radiology at Memorial Sloan Kettering Cancer Center. He currently serves as an Associate Member (Associate Professor equivalent) and Laboratory Head, with secondary affiliations at Gerstner Sloan Kettering Graduate School of Biomedical Sciences and Weill Cornell Medical College.

Dr. Reiner’s scientific career originated at Technische Universität München, where he received his PhD in 2009 focusing on the synthesis of transition-metal containing protease inhibitors. After graduation, he accepted a position as a post-doctoral fellow at the Center for Systems Biology at Massachusetts General Hospital under the mentorship of Ralph Weissleder and was promoted to Instructor at Harvard Medical School in 2011. The following year, he transferred to Memorial Sloan Kettering Cancer Center.

At Memorial Sloan Kettering, Dr. Reiner has built a highly interdisciplinary team of chemists, radiochemists, cell biologists and cancer biologists with the singular focus of designing, validating and translating novel imaging agents and radiotherapeutics. He has published about 90 peer-reviewed paper and has mentored 15 PhD students and postdoctoral fellows.

One of the signature research achievements of Dr. Reiner’s Lab is the development of novel PARP imaging agents and radiotherapeutics, a target and biomarker he helped pioneer during his time at Massachusetts General Hospital. His work has not only inspired many other research groups to enter this field, but has also resulted in the design of SBI001, THG-008 and THG-009, three small molecules that have transitioned from the preclinical to the clinical space.